|
Univariate analysis of relapse-free survival for conventional prognostic factors in the test set cohort |
||||||
| Factor |
n/313 |
Divisions |
n |
Median RFS, years (95% CI) |
HR (95% CI) |
P |
|
|
||||||
| Overall |
313 |
5.2 (3.9–6.5) |
||||
| Age |
313 |
≤40 |
34 |
2.9 (1.3–4.5) |
1 |
|
| >40 |
279 |
5.6 (4.2–7.0) |
0.74 (0.48–1.13) |
0.2 |
||
| Menopausal status |
307 |
Pre |
104 |
3.7 (2.1–5.2) |
1 |
|
| Post |
203 |
6.0 (3.9–8.2) |
0.79 (0.59–1.05) |
0.1 |
||
| Tumor grade |
297 |
1, 2 |
5, 101 |
9.5 (4.9–14.2) |
1 |
|
| 3 |
191 |
4.0 (3.3–4.8) |
1.24 (1.06–1.45) |
0.007 |
||
| Tumor size, cm |
308 |
0 to 2 |
100 |
11.0 |
1 |
|
| >2 to 5 |
173 |
4.5 (3.5–5.6) |
1.67 (1.21–2.33) |
0.002 |
||
| >5 |
35 |
3.0 (0–6.2) |
1.55 (0.95–2.54) |
0.08 |
||
| Pathological ER statusa |
306 |
Negative |
72 |
2.0 (0.9–3.0) |
1 |
|
| Positive |
234 |
6.8 (4.0–9.5) |
0.53 (0.38–0.72) |
0.00007 |
||
| Lymphovascular invasion |
293 |
Negative |
49 |
12.0 (5.3–18.8) |
1 |
|
| Positive |
244 |
4.5 (3.5–5.4) |
1.73 (1.13–2.66) |
0.01 |
||
| Percentage of positive nodes |
313 |
0–50 |
121 |
9.2 (5.7–12.8) |
1 |
|
| >50–99 |
142 |
4.8 (3.5–6.2) |
1.52 (1.11–2.09) |
0.01 |
||
| 100% |
50 |
3.1 (1.8–4.4) |
1.96 (1.30–2.94) |
0.001 |
||
| Number of positive nodes |
313 |
4–9 |
235 |
5.3 (3.9–6.7) |
1 |
|
| ≥10 |
78 |
4.8 (2.1–7.6) |
1.16 (0.85–1.60) |
0.4 |
||
| Histology |
313 |
Ductal |
279 |
5.1 (3.8–6.5) |
1 |
|
| Lobular |
34 |
6.4 (2.7–10.1) |
1.16 (0.76–1.77) |
0.5 |
||
|
P, significance for the comparison of hazard ratios; ER, estrogen receptor; RFS, relapse-free survival; CI, confidence interval; HR, hazard ratio. aPathological ER status at diagnosis. | ||||||
Crabb et al. Breast Cancer Research 2008 10:R6 doi:10.1186/bcr1847 |
||||||